Sensitive Line Probe Assay That Simultaneously Detects Mutations Conveying Resistance to Lamivudine and Adefovir
Open Access
- 1 March 2006
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (3), 1094-1097
- https://doi.org/10.1128/jcm.44.3.1094-1097.2006
Abstract
The INNO-LiPA HBV DR v2 assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.Keywords
This publication has 7 references indexed in Scilit:
- Liver transplantation for chronic hepatitis B with lamivudine‐resistant YMDD mutant using add‐on adefovir dipivoxil plus lamivudineLiver Transplantation, 2005
- Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutantsLiver Transplantation, 2005
- Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patientsHepatology, 2003
- Rapid and Sensitive Assays for Determination of Hepatitis B Virus (HBV) Genotypes and Detection of HBV Precore and Core Promoter VariantsJournal of Clinical Microbiology, 2003
- Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR AssayJournal of Clinical Microbiology, 2002
- Different hepatitis b virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversionHepatology, 1999
- Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxisHepatology, 1998